Loading...

FITC anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136
C57BL/6 mouse splenocytes were stained with NK1.1 (clone PK136) FITC and NKG2D PE.
  • PK136
    C57BL/6 mouse splenocytes were stained with NK1.1 (clone PK136) FITC and NKG2D PE.
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
108705 50 µg 38€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108706 500 µg 106€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References

(PubMed link indicates BioLegend citation)
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Zaman R, et al. 2021. Immunity. :. PubMed
  2. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  3. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  4. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  5. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  6. Chung YM, et al. 2022. Am J Cancer Res. 12:1241. PubMed
  7. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  8. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  9. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  10. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  11. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  12. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  13. Fullertona A, et al. 2013. Toxicol Appl Pharmacol. 266:317. PubMed
  14. Li X, et al. 2014. PLoS One. 9:108192. PubMed
  15. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  16. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  17. Lissner MM, et al. 2020. Elife. 9:00. PubMed
  18. Köchl R, et al. 2020. Elife. 9:00. PubMed
  19. Song Y, et al. 2016. Mol Cancer Ther. 15: 2413 - 2421. PubMed
  20. Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed
  21. Benechet AP, et al. 2019. Nature. 574:200. PubMed
  22. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  23. Kimball AS et al. 2019. Immunity. 51(2):258-271 . PubMed
  24. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  25. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  26. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  27. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  28. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  29. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  30. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  31. Pardy RD, et al. 2021. Nat Commun. 12:4051. PubMed
  32. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  33. Calcinotto A, et al. 2018. Nat Commun. 9:4832. PubMed
  34. Chung YM, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  36. Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed
  37. Wolf KG, et al. 2022. JVS Vasc Sci. 3:336. PubMed
  38. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  39. Giampazolias E, et al. 2021. Cell. . PubMed
  40. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  41. Shahzad KA, et al. 2018. Drug Deliv. 25:703. PubMed
  42. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  43. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  44. Bronisz–Budzynska I, et al. 2019. Skelet Muscle. 9:22. PubMed
  45. Ruscher R, et al. 2018. Bio Protoc. 8:e2757. PubMed
  46. Lam KC, et al. 2021. Cell. 184:5338. PubMed
  47. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  48. Valkenburg S, et al. 2016. Sci Rep. 6:22666. PubMed
  49. Yuan C, et al. 2015. Biochem Biophys Res Commun. 464: 249-255. PubMed
  50. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  51. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  52. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  53. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  54. Bárcena C et al. 2019. EBioMedicine. 43:513-524 . PubMed
  55. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  56. Werner A, et al. 2021. iScience. 24:103076. PubMed
  57. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  58. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  59. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  60. Wang X, et al. 2022. Elife. 11:. PubMed
  61. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  62. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  63. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  64. Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
RRID
AB_313392 (BioLegend Cat. No. 108705)
AB_313393 (BioLegend Cat. No. 108706)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Go To Top Version: 2    Revision Date: 12/08/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account